Company

Beckman Coulter Genomics, headquartered in Danvers, Massachusetts, is a leading provider of genomic services and nucleic acid purification products, serving life-science researchers and the pharmaceutical industry throughout the world. By providing technical expertise, combined with personalized service, Beckman Coulter Genomics delivers the highest quality data, robust analyses and innovative thinking.

The new company, which combines Agencourt Bioscience and Cogenics, offers researchers a single genomic services resource with expanded global capabilities.

“Through the creation of Beckman Coulter Genomics, we have successfully brought together the industry’s leading genomic service providers to offer our customers the highest quality data and analysis,” said Richard Creager, Ph.D., Beckman Coulter group vice president of Immunoassay, Molecular Diagnostics and Genomic Services.

From classic to cutting-edge, Beckman Coulter Genomics has expertise and experience on a wide range of genomic technology platforms and is dedicated to delivering the highest quality results. Services currently available include sequencing, sample preparation, genotyping, gene expression, biologics testing, with support for all levels of regulatory compliance, including Clinical Laboratory Improvement Amendments (CLIA). In addition, Beckman Coulter Genomics offers all three commercially available next-generation sequencing platforms: Roche 454 Genome Sequencer FLX with Titanium, Applied Biosystems SOLiD* and Illumina* Genome Analyzer.

“We understand that each customer, each sample and each study is unique and extremely important,” said Susan Evans, Ph.D., general manager of Beckman Coulter Genomics. “That is why we strive to create a partnership with each customer through a consistent and personalized approach. Our experienced team has the energy and resolve needed to deliver high-quality results scientists can trust.”

Beckman Coulter Genomics also offers an array of nucleic acid purification products for customers who wish to improve and automate their own genetic and genomic discovery initiatives.